Global Covid-19 Vaccine Market Growth (Status and Outlook) 2025-2031

The global Covid-19 Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.





The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

North America is the largest consumption place, with a consumption market share nearly 53.8% in 2026, Europe is the second largest consumption place with the consumption market share of 24.61% in 2026.

LPI (LP Information)' newest research report, the “Covid-19 Vaccine Industry Forecast” looks at past sales and reviews total world Covid-19 Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Covid-19 Vaccine sales for 2025 through 2031. With Covid-19 Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Covid-19 Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Covid-19 Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Covid-19 Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Covid-19 Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Covid-19 Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Covid-19 Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Covid-19 Vaccine market by product type, application, key players and key regions and countries.

Segmentation by Type:
DNA
Non-replicating Viral Vector
Protein Subunit
RNA
Others

Segmentation by Application:
Adults
Children

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
Johnson＆Johnson
Heat Biologics
Sanofi

Please note: The report will take approximately 2 business days to prepare and deliver.